Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
12/2003
12/04/2003CA2487811A1 Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487303A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003CA2487143A1 Regulation of novel human asparagine-hydroxylases
12/04/2003CA2487112A1 Neuregulin based methods and compositions for treating cardiovascular diseases
12/04/2003CA2486967A1 Cardiolipin compositions their methods of preparation and use
12/04/2003CA2486918A1 Novel chimeric cd154
12/04/2003CA2486408A1 Methods and compositions for regulation and manipulation of steroidogenesis
12/04/2003CA2485976A1 Increased delivery of a nucleic acid construct in vivo by the poly-l-glutamate (plg) system
12/04/2003CA2485816A1 Vaccines
12/04/2003CA2485733A1 Vaccines
12/04/2003CA2485184A1 Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/03/2003EP1367396A1 Diagnostics and therapeutics for diseases associated with chemokine receptor 10 (CCR10)
12/03/2003EP1366772A1 Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same
12/03/2003EP1366180A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
12/03/2003EP1366174A2 Sid polypeptides binding to pathogenic strain of the hepatitis c virus
12/03/2003EP1366169A2 Antigenic proteins of shrimp white spot syndrome virus and uses thereof
12/03/2003EP1366167A2 Biological organism for preparing pharmaceutical compositions for treating mammals
12/03/2003EP1366165A2 G-protein coupled receptors
12/03/2003EP1366164A1 Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals
12/03/2003EP1366160A2 Mini-dystrophin nucleic acid and peptide sequences
12/03/2003EP1366150A2 Use of protein histidine phosphatase
12/03/2003EP1366144A2 A device for preparing cells
12/03/2003EP1366079A2 Nuclear hormone receptor ligand binding domain
12/03/2003EP1366077A2 PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
12/03/2003EP1366071A2 Dna-sequences, which code for an apoptosis signal transduction protein
12/03/2003EP1365804A2 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
12/03/2003EP1365794A2 Prevention and treatment of sexual arousal disorders
12/03/2003EP1365774A2 Use of zwitterionic polysaccharides for the specific modulation of immune processes
12/03/2003EP1064306B1 Nephrin gene and protein
12/03/2003EP0832196B1 Immortalization and disimmortalization of cells
12/03/2003CN1460181A Nucleic acid sequences and protein involved in cellular senescence
12/03/2003CN1459317A Targeting-fusion DNA vaccine for caries-prevention, and its prepn. method
12/03/2003CN1129666C Human tissue inhibitor of metalloproteinase -4
12/03/2003CN1129454C DNA vaccine for foot and mouth disease
12/02/2003US6657104 Cell-based, and whole-animal-based assays for detecting substances having therapeutic activity toward cardiac hypertrophy.
12/02/2003US6657047 Nucleotide sequences coding polypeptide for use in the treatment of tumors, inflammation, psoriasis, rheumatoid arthritis, cardiovascular and vision disorders
12/02/2003US6656918 Contacting the ductal epithelium of the exocrine gland with epithelium destroying agents such as ethanol and vaccinia virus
12/02/2003US6656917 Compositions and methods for targeted enzymatic release of cell regulatory compounds
12/02/2003US6656916 Glucocorticoid enhancement of gene expression
12/02/2003US6656734 Compositions for the delivery of polynucleotides to cells
12/02/2003US6656730 Attached to an arylpropionic acid that interacts with human serum albumin; acid is ibuprofen, suprofen, ketoprofen, (S)-(+)- pranoprofen, or carprofen.
12/02/2003US6656727 A retroviral vector of a heterologous nucleic acid sequence as well as at least one sequence allowing site-specific integration of the sequence into a non-coding region of a genome; gene therapy of genetic defects; viricides
12/02/2003US6656713 Compounds and methods for modulating activation of NF-κB
12/02/2003US6656707 Nucleic acid molecules encoding the same; vectors, host cells, pharmaceutical compositions, selective binding agents and methods for production; antagonists and agonists; bactericides; viricides
12/02/2003US6656706 Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
12/02/2003US6656704 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
12/02/2003US6656698 12832, a novel human kinase-like molecule and uses thereof
12/02/2003US6656681 Polycystic kidney disease 12 gene and uses thereof
12/02/2003US6656679 Heat shock protein-based vaccines and immunotherapies
12/02/2003US6656480 Nucleotide sequences which code polypeptide for use the treatment of mammary gland cancer
12/02/2003US6656475 Modulating growth of muscle or adipose tissue in eukaryotic organism using agent that affects myostatin signal transduction
11/2003
11/29/2003WO2003096988A2 Tr4/tr2 response elements
11/29/2003CA2486351A1 Tr4/tr2 response elements
11/27/2003WO2003098223A2 A method for killing cells by inhibiting histone activity in the cell
11/27/2003WO2003097871A2 Marker molecules associated with lung tumors
11/27/2003WO2003097843A1 Tumor suppressor locus in prostate cancer
11/27/2003WO2003097838A1 Plasmid stabilisation in vivo
11/27/2003WO2003097834A2 A method for in vitro molecular evolution of protein function
11/27/2003WO2003097823A1 Regulation of human serine/threonine kinase
11/27/2003WO2003097805A2 Delivery of nucleic acid-like compounds
11/27/2003WO2003097799A2 HTLV-I TAX INDUCED KILLING OF p53 NULL CANCER CELLS
11/27/2003WO2003097798A2 Carotene synthase gene and uses therefor
11/27/2003WO2003097691A1 Sodium channel regulators and modulators
11/27/2003WO2003097687A2 Neuroprotective polypeptides and methods of use
11/27/2003WO2003097686A1 Novel protein, its dna and use thereof
11/27/2003WO2003097158A2 Electroporation-mediated transfection of the salivary gland
11/27/2003WO2003097107A2 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
11/27/2003WO2003097089A2 Attenuation of metapneumovirus
11/27/2003WO2003096981A2 Method of modulating angiogenesis
11/27/2003WO2003096967A2 Dna vaccines encoding heat shock proteins
11/27/2003WO2003080638A9 Antisense iap nucleobase oligomers and uses thereof
11/27/2003WO2003078568A3 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
11/27/2003WO2003073981A3 Novel of cytokine inhibitors
11/27/2003WO2003072045A3 Treatment and prevention of aids progression and methods of using same
11/27/2003WO2003059382A3 Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression
11/27/2003WO2003055505A3 Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders
11/27/2003WO2003051383A3 Use of hmgb proteins and nucleic acids that code therefor
11/27/2003WO2003035883A3 Methods and compositions for inducing tumor-specific cytotoxicity
11/27/2003WO2003029459A3 Micro-rna molecules
11/27/2003WO2003028656A3 Adjuvant compositions
11/27/2003WO2003020759A3 A caspase- 8 binding protein, its preparation and use
11/27/2003WO2003018636A3 Chimaeric peptides of insulin, their compositions and use in treating diabetes
11/27/2003WO2003008443A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/27/2003WO2003006611A3 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE
11/27/2003WO2002099059A3 U5-200KDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
11/27/2003WO2002092626A3 Cleavage and polyadenylation complex of precursor mrna
11/27/2003WO2002086156A3 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
11/27/2003WO2002086113A3 Enzyme and snp marker for disease
11/27/2003WO2002085940A3 New polynucleotides and polypeptides of the erythropoietin gene
11/27/2003WO2002072632A3 Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof.
11/27/2003WO2002064805A3 Replication competent non-mammalian retroviral vectors
11/27/2003WO2002060950B1 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
11/27/2003WO2002049625A3 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
11/27/2003WO2002046424A3 Fibroblast growth factors
11/27/2003US20030221209 Modified proteinase inhibitors
11/27/2003US20030221206 Using in vitro fertilization to produce gentically engineered animals for use as models for prevention and treatment of disease
11/27/2003US20030221203 High efficiency regulatable gene expression system
11/27/2003US20030221199 Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
1 ... 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 ... 870